1-3 of 3
Marko Kavcic, MD
Close
Sort by
Journal Articles

Accuracy Of Adverse Event Reporting Compared To Patient Chart Abstraction On a Phase III NCI-Funded Clinical Trial For Pediatric Acute Myeloid Leukemia: A Report From The Children’s Oncology Group

Tamara P. Miller, MD, Marko Kavcic, MD, Yimei Li, Todd A. Alonzo, PhD, Matt Hall, PhD, Yuan-Shung Huang, MS, Robert B. Gerbing, MA, Brian T. Fisher, DO, MSCE, Selina Luger, MD, David Rubin, MD, MSCE, Andrea Troxel, ScD, Lillian Sung, MD, PhD, Alan S. Gamis, MD, MPH, Richard Aplenc, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 931.
https://doi.org/10.1182/blood.V122.21.931.931
Published: 2013
Journal Articles

Variability in Antifungal Use for Pediatric Acute Myeloid Leukemia At Children's Hospitals Across the United States

Marko Kavcic, MD, Brian T. Fisher, DO, MSCE, Jeffrey S. Gerber, MD, PhD, Kateri H. Leckerman, MS, Yimei Li, PhD, Yuan-Shung Huang, MS, Alix E. Seif, MD, MPH, Kari Torp, Rochelle Bagatell, MD, Richard Aplenc, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 4278.
https://doi.org/10.1182/blood.V120.21.4278.4278
Published: 2012
Journal Articles

Mortality and Resource Utilization in Children with De Novo Acute Myeloid Leukemia Treated with Chemotherapy and Gemtuzumab Ozogamicin in the United States

Marko Kavcic, MD, Brian T. Fisher, DO, MSCE, Yimei Li, PhD, Alix E. Seif, MD, MPH, Kari Torp, Yuan-Shung Huang, MS, Grace E. Lee, MD, Sarah K Tasian, MD, Ami V. Desai, MD, Marijana Vujkovic, PhD, Rochelle Bagatell, MD, Richard Aplenc, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 4283.
https://doi.org/10.1182/blood.V120.21.4283.4283
Published: 2012